Noble Financial keeps USD 12.00 target for Ocugen stock

Published on 10/27/2026 at 20:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Ocugen booked USD 1.49 million in second-quarter 2026 revenue. Ocugen stock costs EUR 0.67 on October 27, 2026 at 8:05 p.m. CEST.

Noble Financial keeps target

Noble Financial reiterated a USD 12.00 target for Ocugen on September 29, 2026.
Ocugen reported USD 1.49 million in revenue for the second quarter of 2026.
Ocugen stock costs EUR 0.67 at Lang & Schwarz on October 27, 2026 at 8:05 p.m. CEST.
Ocugen is scheduled to report third-quarter 2026 results on November 4, 2026.

OCGN, US67577C1053, Illustration mit AI erstellt.

Ocugen (ISIN US67577C1053) has a USD 12.00 analyst target from Noble Financial, while the biotechnology stock stood at EUR 0.67 at Lang & Schwarz on October 27, 2026 at 8:05 p.m. CEST. Noble Financial reiterated its Buy rating and USD 12.00 target on September 29, 2026, according to The Globe and Mail.

Revenue remains modest

Ocugen reported USD 1.49 million in revenue for the second quarter of 2026, compared with USD 1.53 million in the first quarter. Net loss reached USD 24.88 million in the second quarter, or USD 0.07 per diluted share, versus a USD 19.18 million loss and USD 0.06 per share in the first quarter.

Cash and cash equivalents totaled USD 100.05 million on June 30, 2026, while total assets stood at USD 124.21 million. Operating cash flow was negative USD 12.20 million for the second quarter. These figures place funding and clinical execution alongside the analyst view as the key investor reference points.

Nasdaq price stays near low

Ocugen's primary listing is Nasdaq, where the stock was trading at USD 0.75 on October 27, 2026 at 3:09 p.m. ET, with a market capitalization of USD 254.6 million. Its 52-week range was USD 0.70 to USD 2.73 on the same date, leaving the latest Nasdaq price USD 0.05 above the low and USD 1.98 below the high.

The euro quotation was EUR 0.67 at Lang & Schwarz on October 27, 2026 at 8:05 p.m. CEST. The German quotation gives investors a separate euro trading view, while the Nasdaq price remains the home-market reference for the company's USD valuation.

Results date sets next checkpoint

Ocugen announced on October 22, 2026 that it will provide a business update and report third-quarter 2026 financial results on November 4, 2026, at 8:30 a.m. ET. The date and time come from the company's investor release.

MarketBeat reported on October 24, 2026 that Wall Street Zen downgraded Ocugen from hold to sell, while the broader consensus cited by the outlet remained Moderate Buy with a USD 9.50 average target. The same report said second-quarter revenue was USD 1.49 million and the quarterly loss was USD 0.07 per share.MarketBeat

Ocugen stock and the next report

The November 4 release is the next concrete test for revenue, cash use and clinical progress. The USD 12.00 Noble Financial target and the USD 9.50 consensus cited by MarketBeat remain materially above the latest Nasdaq quotation, but the next company update will provide the next period-specific evidence.

The further course of trading is shown by the continuously updated real-time quote of Ocugen stock.